Skip to main content

Sandoz Seeks High Court Take on Biosimilar Law

Mintz Boston Member and experienced patent litigator Tom Wintner is quoted in this Law360 article covering Sandoz’s efforts to have the U.S. Supreme Court review a Federal Circuit ruling that “found biosimilar makers must wait until their products receive U.S. Food and Drug Administration (FDA) approval before providing 180-day advance notice of sales.” Sandoz claims that the ruling grants extra exclusivity for “no good reason.”

Download Article